Evelo Biosciences, Inc.
EVLO · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | -0.03 | 0.08 |
| FCF Yield | -1,534.20% | -109.35% | -101.07% | -13.24% |
| EV / EBITDA | -1.57 | -3.20 | -1.83 | -8.72 |
| Quality | ||||
| ROIC | -75.39% | -135.82% | -81.20% | -39.75% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.94 | 0.80 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 47.27% | 2.27% | 13.37% | -3.64% |
| Safety | ||||
| Net Debt / EBITDA | -1.51 | -2.25 | -0.98 | -0.15 |
| Interest Coverage | -9.62 | -14.30 | -22.41 | -11.48 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -59.70 | -209.68 | 0.00 | 0.00 |